
How has ophthalmology changed in 2016?
As the end of the year approaches, we wanted to take a look back at the predictions our Editorial Advisory Board members made for 2016 and see how far we’ve come in the last 12 months.
As the end of the year approaches, we wanted to take a look back at the predictions our Editorial Advisory Board members made for 2016 and see how far ophthalmology has come in the last 12 months. To read their original predictions,
A special thanks goes out once again to Peter J. McDonnell, MD, Randall Olson, MD, Andrew G. Lee, MD, Sharon Fekrat, MD, and Robert K. Maloney, MD, for sharing their insights.
Keep a lookout for their thoughts about 2017!
"Where do you see the most growth in the field of ophthalmology?"
Dr. McDonnell anticipated the specialty as a whole would need to adapt to provide more efficient care, to more people, at lower costs.
He wrote about the increasing pressures put on ophthalmologists in a recent editorial, “
Dr. Olson anticipated the approval of the Tecnis Symfony IOL (Abbott) and Light Adjustable Lens IOL (Calhoun Vision), which he said would be game changers in the refractive premium IOL market. Indeed, the big IOL news of the year was
Molecular genetics, small molecules as drug delivery targets, and nanotechnology were the areas Dr. Lee anticipated major advances in during the year. This year,
(Cont.) "Where do you see the most growth in the field of ophthalmology?"
Sharon Fekrat, MD, predicted the most growth in the field would be in imaging technology. From portable devices for
Dr. Maloney saw major advancements coming for femtosecond laser cataract surgery. “Those of us who do this regularly feel we are stepping back into olden times when we do standard cataract surgery,” he said. Many reports over the past year continued to shed light on
"What advances are you anticipating in the coming year?"
Dr. McDonnell greatly anticipated seeing how the
In addition, Dr. McDonnell's hope that corneal crosslinking (CXL) would make its entrance into the U.S. market finally came true this year. Since its approval, CXL has shown to be a safe, effective procedure for
Dr. Olson could not wait to have new options for dry eye products. You may have been living under a rock if you did not hear Shire’s new dry eye drug, Xiidra, was approved by the FDA this year for the treatment of the signs and symptoms of dry eye disease. You can read about the results of the OPUS-3 study
(Cont.) "What advances are you anticipating in the coming year?"
Dr. Lee expected the Argus II Retinal Prosthesis System (Second Sight Medical Products) to become a major player in 2016. Earlier this fall, the company released the device’s
Key advances Dr. Fekrat expected included tele-ophthalmology and self-diagnosis with apps. A
"Where do you think the ophthalmic community will stand a year from now?"
“The number of brilliant, incredibly qualified medical students seeking ophthalmology residencies in the United States today far exceeds the number of available training slots," Dr. McDonnell said in late 2015. "This allows us to be extremely selective. So we have a pipeline of the best and brightest pursuing careers in our specialty, and this obviously augurs well for the continued vibrancy and success of our field.”
Josh Mali, MD, an OT blogger, explained the
"Where do you think the ophthalmic community will stand a year from now?"
Dr. Maloney thought by the end of 2016, ophthalmologists would be using fewer post-op topical drops. Earlier this year we featured some
"What do you see as the major hurdles we will be confronting?"
The consensus among our Editorial Advisory Board members was decreasing reimbursements would pose a challenge for ophthalmologists in 2016. Most ophthalmologists would probably agree this was in fact a struggle. However, ophthalmology as a specialty is very adaptive, and as Dr. Maloney optimistically stated, “we’ll soldier through.”
More:
Related:
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.